Gland Pharma · NSE: GLAND · BSE: 543245
Q3 FY26 results · Oct–Dec 2025
Gland Pharma reported revenue from operations of ₹1,695.36 crore (up 22.5% from Q3 FY25) and net profit of ₹261.48 crore (up 27.7% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,695.36 | 1,384.05 | +22.5% | 1,486.88 | +14.0% |
| Other income | 63.17 | 58.49 | +8.0% | 84.16 | −24.9% |
| Total income | 1,758.54 | 1,442.55 | +21.9% | 1,571.04 | +11.9% |
| Profit before tax | 362.13 | 299.30 | +21.0% | 283.92 | +27.5% |
| Net profit for the period | 261.48 | 204.69 | +27.7% | 183.68 | +42.4% |
| EPS, basic (₹) | 15.87 | 12.42 | +27.8% | 11.15 | +42.3% |
| Net margin (%) | 15.4 | 14.8 | 12.4 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,177.51 | 1,010.78 | +16.5% | 1,074.15 | +9.6% |
| Other income | 60.21 | 65.06 | −7.5% | 82.59 | −27.1% |
| Total income | 1,237.72 | 1,075.85 | +15.0% | 1,156.74 | +7.0% |
| Profit before tax | 412.46 | 394.13 | +4.6% | 408.67 | +0.9% |
| Net profit for the period | 307.85 | 295.12 | +4.3% | 302.00 | +1.9% |
| EPS, basic (₹) | 18.68 | 17.91 | +4.3% | 18.33 | +1.9% |
| Net margin (%) | 26.1 | 29.2 | 28.1 |
Consolidated
- Filed with BSE
- 28 Jan 2026, 17:43 IST
- Board meeting
- 28 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jan 2026, 17:43 IST
- Board meeting
- 28 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE